(S)-3-Methyl 2-(6-(naphthalen-2-yl)-2-oxohexanamido)butanoic acid

ID: ALA3770579

Chembl Id: CHEMBL3770579

PubChem CID: 127029318

Max Phase: Preclinical

Molecular Formula: C21H25NO4

Molecular Weight: 355.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)[C@H](NC(=O)C(=O)CCCCc1ccc2ccccc2c1)C(=O)O

Standard InChI:  InChI=1S/C21H25NO4/c1-14(2)19(21(25)26)22-20(24)18(23)10-6-3-7-15-11-12-16-8-4-5-9-17(16)13-15/h4-5,8-9,11-14,19H,3,6-7,10H2,1-2H3,(H,22,24)(H,25,26)/t19-/m0/s1

Standard InChI Key:  KXUDDRZIASHXGW-IBGZPJMESA-N

Alternative Forms

  1. Parent:

    ALA3770579

    ---

Associated Targets(Human)

PLA2G2A Tchem Phospholipase A2 group IIA (1079 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PLA2G1B Tchem Phospholipase A2 group 1B (720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PLA2G5 Tchem Phospholipase A2 group V (238 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PLA2G10 Tchem Group X secretory phospholipase A2 (219 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 355.43Molecular Weight (Monoisotopic): 355.1784AlogP: 3.35#Rotatable Bonds: 9
Polar Surface Area: 83.47Molecular Species: ACIDHBA: 3HBD: 2
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 3.96CX Basic pKa: CX LogP: 4.57CX LogD: 1.39
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.53Np Likeness Score: 0.06

References

1. Vasilakaki S, Barbayianni E, Leonis G, Papadopoulos MG, Mavromoustakos T, Gelb MH, Kokotos G..  (2016)  Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.,  24  (8): [PMID:26970660] [10.1016/j.bmc.2016.02.040]
2. Vasilakaki S, Barbayianni E, Magrioti V, Pastukhov O, Constantinou-Kokotou V, Huwiler A, Kokotos G..  (2016)  Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cells.,  24  (13): [PMID:27234891] [10.1016/j.bmc.2016.05.017]

Source